期刊文献+

血栓性血小板减少性紫癜临床分析 被引量:1

Clinical Analysis of Thrombotic Thrombocytopenic Purpura
暂未订购
导出
摘要 目的:探讨血栓性血小板减少性紫癜(TTP)的病因、临床特点和治疗效果,以加深对该病的认识。方法:对15例TTP的类型、临床表现、治疗及预后进行回顾性分析。结果:15例中女性9例。原发性TTP10例,继发性TTP5例;5例继发性TTP中,感染所致2例,自身免疫性疾病1例,药物1例,妊娠1例。15例患者均为急性起病。临床主要表现为血小板减少、微血管病性溶血性贫血、神经精神障碍、发热及肾脏损害。5例继发性TTP患者以血浆置换(PE)和病因治疗为主,均治愈。10例原发性TTP采用以血浆置换为主的综合治疗,6例治愈,1例复发,3例死亡。结论:TTP的治疗应强调PE和输注新鲜冰冻血浆的重要性。 Objective: To investigate the pathogenisis, clinical characteristic and therapeutic response of thrombotic thrombocytopenic purpura (TTP). Methods: Clinical manifestations, treatment and prognosis of 15 cases with TTP were analyzed retrospectively. Results: Nine of 15 cases were female. 10 cases were idiopathic TFP and 5 were secondary. The secondary TTP were caused by infection (2 cases), autoimmune disease (1 case), drug (1 case) and pregnancy (1 case). All the patients with TTP developed and progressed rapidly. Clinical manifestations were characterized by thrombocytopenia, microangiopathic hemolytic anemia, neurologie abnormalities, fever and renal involvement. 5 secondary TI'P patients were cured by plasma exchange (PE) and etilogical eradication. 10 idiopathic TTP patients were treated with PE and composite treatments, 6 patients were cured, 1 relapsed and the other 3 patients died. Conclusion: Treatment of TTP should emphasize the importance of PE and fresh frozen plasma infusion.
出处 《内科急危重症杂志》 2009年第4期202-204,共3页 Journal of Critical Care In Internal Medicine
关键词 紫癜 血栓性血小板减少性 vWF多聚体 vWF裂解蛋白酶 血浆置换 临床分析 Purpura Thrombotic thrombocytopenic vWF muhimer vWF cleaving metalloprotease Plasma exchange Clinical analysis
  • 相关文献

参考文献2

二级参考文献22

  • 1[1]Amorosi EL,Ultamann J.E and F.A.C.P. Thrombotic thrombocytopenic purpura: Report of 16 cases and review of the literature.Medicine, 1966,45:139.
  • 2[2]Bums ER, Zucker-Frankling D. Pathologic effects of plasma from patients with thrombotic thrombocytopenic purpura on platelets and cultured vascular endothelial cells. Blood, 1982,60:1030.
  • 3[3]Moake JL. TTP-desperation, empiricism, progress. N Engl J Med, 1991,325:426.
  • 4[4]Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving proteaes in acute thrombotic thrombocytopenic purpura. N Engl J Med,1998,339:1585.
  • 5[5]Furlan M, Robles R, Galbusera M, et al. von Willebrand factor -cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med, 1998,339:1578.
  • 6[6]Fujikawa K, Suzuki H, McMullen B,et al. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood,2001,98:1662.
  • 7[7]Gerritsen HE,Robles R, Lammle B,et al. Partial amino acid sequence of purified von Willebrand factor-cleaving protease . Blood, 2001,98:1654.
  • 8[8]Schultz DR, Arnold PI, Jy W, et al. Anti-CD36 autoantibodies in thrombotic thrombocytopenic purpura and other thrombotic disorders:identification of an 85 KD form of CD36 as a target antingen. Br J Haematol, 1998,103:849.
  • 9[9]Bell WR, Braine HG, Ness PM,et al. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.Clincal experience in 108 patients. N Engl J Med, 1991,325:398.
  • 10[10]Sarode R, Gottschall JL, Aster RH,et al. Thrombotic thrombocytopenic purpura:early and late responders. AM J Haematol.1997,54:102.

共引文献24

同被引文献9

  • 1Rusconi C,Oneglia C,Sabatini T.Failure of low dosage thrombolytic therapy with streptokinase to treat heparin-induced thrombocytopenic-thrombotic syndrome[J].Int J Cardiol,1997,62(1):87-89.
  • 2Tsai HM,Raoufi M,Zhou W,et al.ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura[J].Thromb Haemost,2006,95(5):886-892.
  • 3Allford SL,Machin SJ.Current understanding of the pathophysiology of thrombotic thrombocytopenic purpura[J].J Clin Pathol,2000,53(7):497-501.
  • 4George JN.How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome[J].Blood,2000,96(4):1223-1229.
  • 5von Baeyer H.Plasmapheresis in thrombotic microangiopathy-associated syndromes:review of outcome data derived from clinical trials and open studies[J].Ther Apher,2002,6(4):320-328.
  • 6Murrin RJ,Murray JA.Thrombotic thrombocytopenic purpura:aetiology,pathophysiology and treatment[J].Blood Rev,2006,20(1):51-60.
  • 7Patino W,Sarode R.Successful repeat therapy with rituximab for relapsed thrombotic thrombocytopenic purpura[J].J Clin Apher,2007,22(1):17-20.
  • 8张之南,杨天楹,郝玉书,等.血液病学[M].北京:人民卫生出版社,2005:1792-1794.
  • 9陈婉茜,陈济民,陈婉仪,陈友华,高清平.血栓性血小板减少性紫癜临床分析[J].内科急危重症杂志,2003,9(4):181-182. 被引量:12

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部